© 1996 British Society for Rheumatology
other |
SERUM YKL-40 LEVELS IN HEALTHY CHILDREN AND ADULTS. COMPARISON WITH SERUM AND SYNOVIAL FLUID LEVELS OF YKL-40 IN PATIENTS WITH OSTEOARTHRITIS OR TRAUMA OF THE KNEE JOINT
*Department of Orthopaedic Surgery, University of Copenhagen, Herlev Hospital Denmark
Department of Pulmonary Medicine, Bispebjerg Hospital Denmark
Department of Biology 0322, University of California at San Diego La Jolla, CA, USA
Department of Medicine, Division of Rheumatology, University of Copenhagen, Hvidovre Hospital Denmark
Correspondence to:
Correspondence to: J. S. Johansen, Department of Medicine, Division of Rheumatology 232, University of Copenhagen, Hvidovre Hospital, Kettegard Alle 30, DK-2650 Hvidovre, Denmark.
YKL-40 is a recently discovered human glycoprotein which is related in amino acid sequence to the chitinase protein family. YKL-40 is a major secretory protein of human chondrocytes and synoviocytes, and could play a role in tissue remodelling. The aim of the study was to establish the serum YKL-40 level in normal subjects and to evaluate serum YKL-40 as a marker for osteoarthritis. Serum YKL-40 was 80 µg/1 in healthy children (n = 476) and 102 µg/1 in healthy adults (n = 260). No age or sex differences were found in serum YKL-40 in subjects younger than 70 yr, but thereafter serum YKL-40 increased significantly. Patients with late-stage osteoarthritis of the knee (n = 37) had significantly higher serum YKL-40 (1.5-fold; P < 0.01) compared to healthy age-matched subjects, whereas patients with early-stage osteoarthritis of the knee or recent torn cruciate ligaments or menisci did not have elevated serum YKL-40. The level of YKL-40 in serum and synovial fluid correlated significantly, and 10-fold higher values were found in synovial fluid. YKL-40 levels in serum and synovial fluid of patients with acute severe synovial inflammation were significantly higher (P < 0.05-P 0.001) than those in patients with no, light or moderate synovitis of the knee joint. Furthermore, YKL-40 correlated significantly (P < 0.01) with the amino-terminal propeptide of type III procollagen, but not with serum C-reactive protein. Our data indicate that YKL-40 in synovial fluid and serum may reflect human articular cartilage degradation and the degree of synovial inflammation in the knee joint.
KEY WORDS: Osteoarthritis, Biochemical markers
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. S. Johansen, P. E. Hoyer, L. A. Larsen, P. A. Price, and K. Mollgard YKL-40 Protein Expression in the Early Developing Human Musculoskeletal System J. Histochem. Cytochem., December 1, 2007; 55(12): 1213 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Bigg, R. Wait, A. D. Rowan, and T. E. Cawston The Mammalian Chitinase-like Lectin, YKL-40, Binds Specifically to Type I Collagen and Modulates the Rate of Type I Collagen Fibril Formation J. Biol. Chem., July 28, 2006; 281(30): 21082 - 21095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Mazieres, P Garnero, A Gueguen, M Abbal, L Berdah, M Lequesne, M Nguyen, J-P Salles, E Vignon, and M Dougados Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort Ann Rheum Dis, March 1, 2006; 65(3): 354 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schmidt, J. S. Johansen, P. Sjoegren, I. J. Christensen, B. S. Sorensen, K. Fode, J. Larsen, and H. von der Maase Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma J. Clin. Oncol., February 10, 2006; 24(5): 798 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Johansen, B. V. Jensen, A. Roslind, D. Nielsen, and P. A. Price Serum YKL-40, A New Prognostic Biomarker in Cancer Patients? Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 194 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bernardi, M. Podswiadek, M. Zaninotto, L. Punzi, and M. Plebani YKL-40 as a Marker of Joint Involvement in Inflammatory Bowel Disease Clin. Chem., October 1, 2003; 49(10): 1685 - 1688. [Full Text] [PDF]
|
|
|
|
 |
|
 B. V. Jensen, J. S. Johansen, and P. A. Price High Levels of Serum HER-2/neu and YKL-40 Independently Reflect Aggressiveness of Metastatic Breast Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4423 - 4434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Knorr, F Obermayr, E Bartnik, A Zien, and T Aigner YKL-39 (chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is up regulated in osteoarthritic chondrocytes Ann Rheum Dis, October 1, 2003; 62(10): 995 - 998. [Abstract] [Full Text]
|
|
|
|
|
|
F. Fusetti, T. Pijning, K. H. Kalk, E. Bos, and B. W. Dijkstra Crystal Structure and Carbohydrate-binding Properties of the Human Cartilage Glycoprotein-39 J. Biol. Chem., September 26, 2003; 278(39): 37753 - 37760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Houston, A. D. Recklies, J. C. Krupa, and D. M. F. van Aalten Structure and Ligand-induced Conformational Change of the 39-kDa Glycoprotein from Human Articular Chondrocytes J. Biol. Chem., August 8, 2003; 278(32): 30206 - 30212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Holten-Andersen, I. J. Christensen, H. J. Nielsen, H. Lilja, G. Murphy, V. Jensen, N. Brunner, and T. Piironen Measurement of the Noncomplexed Free Fraction of Tissue Inhibitor of Metalloproteinases 1 in Plasma by Immunoassay Clin. Chem., August 1, 2002; 48(8): 1305 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ostergaard, J. S. Johansen, T. Benfield, P. A. Price, and J. D. Lundgren YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Purulent Meningitis Clin. Vaccine Immunol., May 1, 2002; 9(3): 598 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Register, C. S. Carlson, and M. R. Adams Serum YKL-40 Is Associated with Osteoarthritis and Atherosclerosis in Nonhuman Primates Clin. Chem., December 1, 2001; 47(12): 2159 - 2161. [Full Text] [PDF]
|
|
|
|
|
|
P Garnero, M Piperno, E Gineyts, S Christgau, P D Delmas, and E Vignon Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage Ann Rheum Dis, June 1, 2001; 60(6): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Vos, A. M. M. Miltenburg, K. E. van Meijgaarden, M. van den Heuvel, D. G. Elferink, P. J. M. van Galen, R. A. van Hogezand, E. van Vliet-Daskalopoulou, T. H. M. Ottenhoff, F. C. Breedveld, et al. Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions Rheumatology, December 1, 2000; 39(12): 1326 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Vos, P Steenbakkers, A M M Miltenburg, E Bos, M W van den Heuvel, R A van Hogezand, R R P de Vries, F C Breedveld, and A M H Boots Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions Ann Rheum Dis, July 1, 2000; 59(7): 544 - 548. [Abstract] [Full Text]
|
|
|
|
|
|
S. Harvey, M. Weisman, J. O'Dell, T. Scott, M. K. J. Visor, and C. Swindlehurst Chondrex: new marker of joint disease Clin. Chem., March 1, 1998; 44(3): 509 - 516. [Abstract] [Full Text] [PDF]
|
|